Peptide News Digest

ECO 2026 Wraps, SURMOUNT-MAINTAIN Lancet 7x Maintenance, $28-140 Generic Semaglutide Cost, Crinetics CAREFNDR + Cushing's, HIMS -13%

ECO 2026 closes: SURMOUNT-MAINTAIN Lancet 7x maintenance odds, medRxiv $28-140/year generic semaglutide cost, Crinetics CAREFNDR + Cushing's, HIMS post-Q1.

10 stories · Covering clinical-trials, industry, research

Editor's Note

ECO 2026 closes in Istanbul Friday with the obesity-pharmacology narrative reorganized around two themes: chronic-disease maintenance (SURMOUNT-MAINTAIN + ATTAIN-MAINTAIN dual publication; EASO first-line framework with complication-specific algorithms) and access economics (generic semaglutide patent expiries unlocking a $28-140/person-year production-cost floor by year-end). The SURMOUNT-MAINTAIN paper formalized in The Lancet on May 14 included a framing the daily press picked up: patients on maximum-tolerated tirzepatide are 7x more likely to maintain weight loss versus stopping treatment, and the 5 mg step-down arm is 4x more likely than placebo. A medRxiv preprint from March synthesized API shipment data and projected generic injectable semaglutide at $28-140/person-year and oral formulations at $186-380/person-year — numbers that, paired with the Lancet 'Making Treatment for Obesity More Equitable' editorial, support a working thesis that 84% of the global obesity burden could be reached by end-2026 if device patents and policy coordination fall into place. Hims & Hers closed the week down ~13% post-Q1 print as gross margin compression from the compounded-GLP-1 wind-down landed harder than analysts expected; Motley Fool's May 14 take framed the dip as a buying opportunity, while JPMorgan trimmed its target. On the non-GLP-1 side, Crinetics' May 7 Q1 print disclosed pivotal CAREFNDR Phase 3 first-patient randomization for paltusotine in carcinoid syndrome and a planned Q2 2026 initiation of the seamless Phase 2/3 atumelnant trial in ACTH-dependent Cushing's syndrome; the company also licensed an early preclinical GH receptor antagonist from Ohio University. The Precision Peptide Company signed a strategic marketing deal with Mixed Martial Arts Group Limited on May 8 covering BPC's peptide line across MMA's 800-gym network. ASCO 2026 abstracts drop in six days (May 21) with the peptide oncology slate centered on Bicycle, Avacta, Pfizer, BioVaxys, BriaCell, and the Crinetics SST2 NDC program. Final-day ECO 2026 sessions on tirzepatide maintenance and EASO algorithm implementation set up the May 21 Foundayo Week 5 IQVIA tracker as the next inflection point.

Clinical Trials

SURMOUNT-MAINTAIN Published in The Lancet (May 14): Tirzepatide MTD 7x More Likely to Maintain Weight Loss; 5 mg Step-Down 4x

The Lancet formalized SURMOUNT-MAINTAIN on May 14, 2026, the same day the trial was presented at ECO 2026 in Istanbul. The Phase 3b 112-week study from Dr. Deborah Horn and colleagues at UTHealth Houston re-randomized patients who had reached maximum tolerated dose tirzepatide to continue MTD (15 mg or 10 mg), step down to 5 mg, or switch to placebo. Patients continuing MTD were 7x more likely to maintain their weight loss than those switching to placebo; the 5 mg step-down arm was 4x more likely than placebo. At week 112, MTD continuers preserved all of their initial weight loss; 5 mg-step-down patients lost only 5.6 kg of their initial gains on average. The 'seven times more likely' framing — picked up by EurekAlert and the daily science press — is the cleanest patient-facing summary of maintenance economics published to date.

#tirzepatide #zepbound #surmount-maintain #lancet #maintenance #deborah-horn #eco-2026
Industry

Hims & Hers Closes Week -13% Post-Q1; Motley Fool May 14 Frames the Dip as a Buying Opportunity

Hims & Hers shares fell ~13% after the May 11 Q1 print as $608.1M revenue missed the $616.9M consensus and gross margin compressed from 73% to 65% on the compounded-semaglutide wind-down. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed); Canaccord raised to $32 from $30 (Buy). The Motley Fool published a 'Is HIMS Stock a Buy After Latest Dip?' analysis on May 14 framing the post-print decline as a buying opportunity, citing the 9% subscriber growth to 2.6M, the raised full-year guide ($2.8-3.0B revenue, $275-350M Adjusted EBITDA), and the structural lift from the Novo Nordisk branded-Wegovy distribution deal landing in Q2 books. The split between bullish and cautious analyst takes captures the central tension: high-growth telehealth navigating a margin-dilutive product transition.

#hims-hers #q1-2026 #motley-fool #jpmorgan #canaccord #novo-nordisk #stock-reaction
Research

Lancet Editorial + medRxiv Preprint: Generic Semaglutide Production Cost $28-140/Person-Year, Could Reach 84% of Global Obesity Burden by End-2026

The Lancet's 'Making Treatment for Obesity More Equitable' editorial (March 2026) and an accompanying medRxiv preprint (Hill et al., March 4, 2026) synthesized 2024-2025 active pharmaceutical ingredient shipment data to estimate generic semaglutide production costs at $28-140/person-year for injectable formulations and $186-380/person-year for oral formulations. By the end of 2026, generic injectable semaglutide could be available in 160 countries covering 69% of global T2DM and 84% of clinical obesity. The 10 countries where Novo Nordisk's 2026 patents expired represent 44% of the global population and 48% of the global obesity burden — including Brazil, Canada, China, India, and Turkey. The constraint isn't manufacturing economics; it's device-patent thickets (57% of analyzed semaglutide patents are device patents) and policy coordination (pooled procurement, voluntary licensing, tiered pricing).

#semaglutide #generic-semaglutide #lancet #global-access #patent-expiry #production-cost #equitable-access
Clinical Trials

PepGen Q1 2026 (May 14): FREEDOM2-DM1 5 mg/kg PGN-EDODM1 Cohort Topline — 7.3% Mean Splicing Correction in n=6 Myotonic Dystrophy Patients

PepGen reported Q1 2026 results on May 14 with topline data from the Phase 2 FREEDOM2-DM1 5 mg/kg multiple-ascending-dose cohort. PGN-EDODM1 — the company's peptide-conjugated phosphorodiamidate morpholino oligomer for myotonic dystrophy type 1 (DM1) — produced a mean splicing correction of 7.3% in 6 treated patients vs 6.8% in 2 placebo patients, with no serious adverse events and mainly mild treatment-emergent adverse events. The 10 mg/kg cohort is fully enrolled with data expected H2 2026; the 12.5 mg/kg cohort readout is expected in 2027. PepGen received regulatory clearance to initiate FREEDOM2 sites in South Korea, Australia, and New Zealand to add to existing sites in Canada and the UK. Q1 net loss of $17.8M (vs $30.2M a year earlier); $132.3M cash supports operations through the 12.5 mg/kg MAD readout into 2H 2027. The DM1 program is PepGen's lead clinical asset following the April DMD program discontinuation; it competes with Vertex/Entrada's VX-670 cyclic peptide-oligonucleotide (GALILEO Phase 1/2, H2 2026 readout).

#pepgen #pgn-edodm1 #freedom2 #myotonic-dystrophy #dm1 #peptide-oligonucleotide #q1-2026
Clinical Trials

Crinetics Atumelnant Phase 2/3 Cushing's Syndrome Q2 2026 Initiation + Ohio University Growth Hormone Receptor Antagonist License

Crinetics also disclosed in the May 7 Q1 update that the company is on track to initiate a seamless Phase 2/3 trial of atumelnant in ACTH-dependent Cushing's syndrome in Q2 2026. The trial will assess efficacy in a broad population including Cushing's disease and ectopic ACTH syndrome. Atumelnant is also in Phase 3 for congenital adrenal hyperplasia. Separately, Crinetics announced an exclusive license agreement with Ohio University to develop an early-preclinical growth hormone receptor antagonist (GHRA) for acromegaly — a mechanism complementary to paltusotine's SST2 agonism that would compete in the same indication once both reach market.

#crinetics #atumelnant #cushings-syndrome #growth-hormone-receptor-antagonist #ohio-university #acromegaly
Industry

The Precision Peptide Company + MMA Group Strategic Marketing Partnership (May 8): Peptide Distribution Across 800-Gym Network

The Precision Peptide Company (BPC) announced a strategic exclusive marketing partnership on May 8 with Mixed Martial Arts Group Limited (MMA), covering distribution of BPC's peptide product line through MMA's network of approximately 530,000 user profiles, 75,000 active students, and 800 verified gyms globally. The revenue-sharing arrangement splits net revenue 50/50 between the two companies for the first 12 months, then shifts to 75% BPC / 25% MMA for the remainder of the term. The deal taps into the broader consumer peptide wellness market projected to approach $300B (per the May 12 GlobeNewswire industry report) and signals the increasingly mainstream integration of peptide products into the combat-sports and broader athletic-performance distribution channels ahead of the July 23-24 PCAC meeting.

#precision-peptide-company #mma-group #peptide-wellness #consumer-products #athletic-performance #distribution-partnership
Industry

ECO 2026 Closes Friday May 15 with Maintenance Pivot + EASO First-Line Framework as Central Narratives

The 33rd European Congress on Obesity closes in Istanbul on Friday May 15 after four days that reframed the obesity-pharmacology conversation around two themes. First, maintenance: the SURMOUNT-MAINTAIN Lancet publication, ATTAIN-MAINTAIN Nature Medicine publication, and Wegovy STEP UP early-responder analyses gave prescribers Phase 3 evidence for dose tapering and switching strategies — moving past the 'how much weight will I lose' question to 'how do I stay there'. Second, guideline alignment: the EASO 2026 Nature Medicine framework formally privileged semaglutide and tirzepatide as first-line therapy across most obesity complications, with complication-specific differentiation (tirzepatide for OSA/MASH; semaglutide for OA/CVD/MASH-fibrosis). Caliway CBL-514 + GLP-1R combination preclinical data and Ascletis next-generation amylin and dual-incretin candidates rounded out the four-day program.

#eco-2026 #istanbul #maintenance #easo-framework #convergence-week #obesity-pharmacology
Industry

TIDES USA 2026 Closed Thursday May 14 in Boston — Bachem, PolyPeptide, CordenPharma CMC Panels Centered on Macromolecule Scale-Up

TIDES USA 2026 wrapped at the Hynes Convention Center in Boston on Thursday May 14 after four days of peptide and oligonucleotide CDMO programming. The CMC strategy tracks featured Bachem, PolyPeptide, CordenPharma, AmbioPharm, and Gilead on GMP capacity, large-scale SPPS economics, and the supply-chain economics of oral macromolecule manufacturing. The closing-day Robert Langer keynote framed peptide-LNP delivery as the next major engineering frontier. The conference concluded with Catalent's Zydis fast-dispersion + oral macromolecule platform presentations and Novo Nordisk's CMC strategy panel on oral semaglutide and the next-generation amycretin program. The week's combined manufacturing footprint (TIDES + the PolyPeptide EUR 200M credit facility on May 9 + the May 6 Lilly Lebanon $4.5B investment) anchors the CDMO buildout heading toward the 2028 capacity targets.

#tides-usa-2026 #boston #bachem #polypeptide #cordenpharma #peptide-cdmo #manufacturing-capacity
Industry

Lilly Centessa $7.8B Orexin Partnership Detail Continues to Shape Lilly's Diversification Beyond GLP-1

Eli Lilly's $7.8B Centessa Pharmaceuticals partnership announced in March 2026 continues to anchor the company's pipeline diversification beyond the GLP-1 franchise. Centessa's lead programs include orexin-2 receptor agonist peptides for narcolepsy and other CNS indications, with multiple Phase 1/2 readouts due across 2026-2027. The deal joins Lilly's $7B Kelonia Therapeutics acquisition (in vivo CAR-T platform) and $2.25B Profluent collaboration (AI-designed recombinase genetic medicine) as part of a multi-vertical diversification strategy. The $4.5B Lebanon Indiana LEAP District expansion announced May 6 (for Foundayo and retatrutide manufacturing) signals the GLP-1 franchise remains the cash cow, but the company is actively building optionality outside the obesity-pharmacology lane heading into the 2031 tirzepatide patent cliff.

#eli-lilly #centessa #orexin #narcolepsy #diversification #lebanon-indiana #patent-cliff
Industry

Foundayo Week 5 IQVIA Tracker Expected Mid-Week — Citi Note Awaited

The next Foundayo IQVIA prescription tracker update is expected from Citi mid-week May 18-20, covering the week ending May 8. Week 4 hit 7,335 prescriptions per the May 8 Citi note with Lilly executives citing 20,000 total patients (~35% via telehealth not captured in the retail-only IQVIA data). Citi's projected $146M Q2 revenue and $1.6B full-year 2026 estimate continue to anchor the analyst consensus. Lilly executives have asked analysts for 8-12 weeks of data before reading commercial trajectory through pharmacy-fill noise; the Week 5 reading is the first post-PBM-coverage-expansion data point as the two largest US PBMs went live with Foundayo coverage mid-May. The Wegovy pill remains roughly 60-70x ahead on weekly volume (>440K in the week ending May 1 per Novo's Q1 commentary).

#foundayo #orforglipron #eli-lilly #iqvia #citi #week-5 #launch-tracker